JPRN-jRCT1031210517进行中（未招募）未知
Investigator-initiated clinical trial, phase I trial, and accompanying st udies investigating the safety and immunogenicity of booster vaccination against COVID-19 (KD-414)
Koga Michiko0 个研究点目标入组 160 人开始时间: 2021年12月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria are targeted.
- •Group who are 20 to under 65 years and finished two intramuscular injections of Pfizer Comirnaty
- •1. Subjects who are 20 years old or older and under 65 years old at the time of obtaining consent
- •2. Subjects who have been vaccinated twice with Pfizer Comirnaty intramuscular injection before receiving this investigational drug and 6-12 months have passed since the first vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who are 65 years or older and finished two intramuscular injections of Pfizer Comirnaty
- •1. Subjects aged 65 and over at the time of obtaining consent
- •2. Subjects who have been vaccinated twice with Pfizer Comirnaty intramuscular injection before receiving this investigational drug and 6-12 months have passed since the first vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who are 20 to under 65 years and finished two intramuscular injections of Takeda/Moderna vaccine
- •1. Subjects who are 20 years old or older and under 65 years old at the time of obtaining consent
- •2. Subjects who have been vaccinated twice with Takeda/Moderna vaccine intramuscular injection before receiving this investigational drug and 6-12 months have passed since the first vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who are 65 years or older and finished two intramuscular injections of Takeda/Moderna vaccine
- •1. Subjects aged 65 and over at the time of obtaining consent
- •2. Subjects who have been vaccinated twice with Takeda/Moderna vaccine intramuscular injection before receiving this investigational drug and 6-12 months have passed since the first vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who have been vaccinated with Pfizer Comirnaty intramuscular injection only once
- •1. Subjects who are 20 years old or older at the time of obtaining consent
- •2. Subjects who have been vaccinated once with Pfizer Comirnaty intramuscular injection before receiving this investigational drug and 6-12 months have passed since the vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who have been vaccinated with Takeda/Moderna vaccine intramuscular injection only once
- •1. Subjects who are 20 years old or older at the time of obtaining consent
- •2. Subjects who have been vaccinated once with Takeda/Moderna vaccine intramuscular injection before receiving this investigational drug and 6-12 months have passed since the vaccine.
- •3. Subjects with no apparent history of SARS-CoV-2 infection prior to inoculation of this investigational drug
- •4. Subjects who can obtain written consent
- •Group who have been vaccinated with Pfizer Comirnaty intramuscular injection twice with a history of SARS-CoV-2 infection
- •1. Those who are 20 years of age or older at the time of obtaining consent
- •2. Subjects who ha
排除标准
- •1.Subjects who tested positive for SARS-CoV-2 by a PCR test at screening,
- •2.Subjects with COVID-19,
- •3.Close contact with COVID-19 patients at the time of the inoculation
- •4.Subjects with a history of administration of anti-SARS-CoV-2 monoclonal antibody within three months before the inoculation of the investigational drug
- •5.Subjects who have developed anaphylaxis due to a component of the investigational drug (thimerosal)
- •6.Pregnant women, women who may be pregnant, women who wish to become pregnant by four weeks after the inoculation of the investigational drug, women who are breastfeeding
- •7.Subjects with progressive ossifying fibrodysplasia
- •8.Subjects with underlying diseases such as severe cardiovascular disease, kidney disease, liver disease, blood disease, growth disorder, respiratory disease and diabetes etc
- •9.Subjects who have had the fever (excluding the feeling of heat at the inoculation site) within two days after the vaccination except for the COVID-19 preventive vaccine, and those who have had symptoms suspected of allergies such as a systemic rash (cause) Not applicable if it is confirmed that the ingredient is not contained in the investigational drug)
- •10.Subjects who have a history of convulsions in the past
- •11.Subjects having been diagnosed with immunodeficiency or having a close relative with congenital immunodeficiency,
- •12.Subjects who have experienced documented anaphylaxis caused by an ingredient of the investigational product (thimerosal),
- •13.Subjects who participated in other clinical trials or clinical trials within 120 days from the date of inoculation of the study drug, or subjects who plan to participate by the end of the follow-up period of this study.
- •14.Subjects who have received transfusion or a gamma globulin preparation within three months (90 days), or a bolus therapy (>=200 mg/kg) with a gamma globulin preparation within six months (180 days), prior to the date of the first dose of study product,
- •15.Subject who have received any treatments that may affect the immune function within six months (180 days) prior to the date of the first dose of study product, including radiotherapy, immunosuppressants (except for external use), immunosuppressive therapy, antirheumatics, adrenocorticotropic hormones, or corticosteroids (treatment at prednisolone equivalent doses >=2 mg/kg/day for >=14 days, except for external use.),
- •16.Subjects who are judged by the principal investigator or the sub-investigator as ineligible for the study as a result of the screening test,
- •17.Subject being otherwise ineligible for this study in the principal investigator's or sub-investigator's opinion.
研究者
相似试验
进行中（未招募）
1 期
The investigator-initiated clinical trial, booster vaccination against COVID-19 (KD-414)Prevention of COVID-19JPRN-jRCT2031210503Koga Michiko160
招募中
1 期
Phase I investigator-initiated clinical trial against differentiated thyroid cancer using TAH-1005thyroid cancerJPRN-jRCT2051210144Watabe Tadashi32
尚未招募
不适用
Investigator-initiated phase I/IIa clinical trial to assess the safety and efficacy of 11beta-HSD1 inhibitor in patients with the refractory Cushing syndrome and subclinical Cushing syndrome.The refractory Cushing syndrome and subclinical Cushing syndrome.JPRN-UMIN000024482Kyushu University Hospital16
招募中
1 期
MIKE-1Patients with untreated, non-resectable pancreatic cancerUnresectable pancreatic cancerD021441JPRN-jRCT2041210056Kawashima Hiroki55
已完成
1 期
Phase I investigator initiated clinical trial using a novel WT1 peptide vaccine for patients with metastatic pancreatic cancerpancreatic cancerJPRN-UMIN000029428Wakayama Medical University6